|
1
|
Guidelines for the use and interpretation of assays for monitoring autophagy.
|
Autophagy
|
2012
|
20.08
|
|
2
|
Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein.
|
Blood
|
2008
|
3.65
|
|
3
|
Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors.
|
J Clin Oncol
|
2002
|
2.55
|
|
4
|
MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity.
|
Cancer Res
|
2010
|
2.22
|
|
5
|
Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer.
|
PLoS One
|
2010
|
1.96
|
|
6
|
Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine).
|
Drug Resist Updat
|
2002
|
1.91
|
|
7
|
Positron emission tomography using 2-deoxy-2-[18F]-fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer; a comparison of different analytical methods.
|
Mol Imaging Biol
|
2003
|
1.86
|
|
8
|
In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant.
|
Cancer Res
|
2005
|
1.76
|
|
9
|
Gemcitabine chemoresistance in pancreatic cancer: molecular mechanisms and potential solutions.
|
Scand J Gastroenterol
|
2009
|
1.53
|
|
10
|
Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity.
|
Mol Cancer Ther
|
2002
|
1.52
|
|
11
|
Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
|
Clin Cancer Res
|
2008
|
1.46
|
|
12
|
Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance.
|
Clin Cancer Res
|
2011
|
1.40
|
|
13
|
Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
|
Mol Pharmacol
|
2008
|
1.37
|
|
14
|
Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin.
|
Clin Cancer Res
|
2011
|
1.35
|
|
15
|
Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia.
|
Blood
|
2002
|
1.30
|
|
16
|
A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer.
|
Clin Cancer Res
|
2010
|
1.29
|
|
17
|
Polymorphisms in folate-related genes and risk of pediatric acute lymphoblastic leukemia.
|
Blood
|
2008
|
1.28
|
|
18
|
Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression.
|
Biochem Pharmacol
|
2003
|
1.27
|
|
19
|
Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome.
|
Blood
|
2002
|
1.27
|
|
20
|
Discovery of N-hydroxyindole-based inhibitors of human lactate dehydrogenase isoform A (LDH-A) as starvation agents against cancer cells.
|
J Med Chem
|
2011
|
1.26
|
|
21
|
The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients.
|
Blood
|
2003
|
1.26
|
|
22
|
Differential activation of cell death and autophagy results in an increased cytotoxic potential for trifluorothymidine compared to 5-fluorouracil in colon cancer cells.
|
Int J Cancer
|
2010
|
1.22
|
|
23
|
Analysis of drug interactions.
|
Methods Mol Biol
|
2011
|
1.17
|
|
24
|
Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia.
|
Blood
|
2005
|
1.10
|
|
25
|
Tyrosine kinase inhibitors: Multi-targeted or single-targeted?
|
World J Clin Oncol
|
2011
|
1.06
|
|
26
|
Loss of multidrug resistance protein 1 expression and folate efflux activity results in a highly concentrative folate transport in human leukemia cells.
|
J Biol Chem
|
2002
|
1.05
|
|
27
|
Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice.
|
Crit Rev Oncol Hematol
|
2011
|
1.04
|
|
28
|
New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies.
|
Anticancer Res
|
2014
|
1.04
|
|
29
|
Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.
|
Biochem Pharmacol
|
2011
|
1.04
|
|
30
|
High-throughput microRNA (miRNAs) arrays unravel the prognostic role of MiR-211 in pancreatic cancer.
|
PLoS One
|
2012
|
1.02
|
|
31
|
Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis.
|
J Pharmacol Exp Ther
|
2012
|
1.02
|
|
32
|
Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models.
|
Invest New Drugs
|
2010
|
1.01
|
|
33
|
In vitro and in vivo antitumor activity of methotrexate conjugated to human serum albumin in human cancer cells.
|
Clin Cancer Res
|
2003
|
1.01
|
|
34
|
Expression microarray analysis and oligo array comparative genomic hybridization of acquired gemcitabine resistance in mouse colon reveals selection for chromosomal aberrations.
|
Cancer Res
|
2005
|
1.00
|
|
35
|
Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies.
|
Cancer Sci
|
2007
|
0.99
|
|
36
|
Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors.
|
Exp Hematol Oncol
|
2013
|
0.98
|
|
37
|
Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells.
|
Mol Cancer Ther
|
2012
|
0.98
|
|
38
|
Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung.
|
Clin Cancer Res
|
2007
|
0.97
|
|
39
|
Trifluorothymidine resistance is associated with decreased thymidine kinase and equilibrative nucleoside transporter expression or increased secretory phospholipase A2.
|
Mol Cancer Ther
|
2010
|
0.95
|
|
40
|
A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors.
|
Clin Cancer Res
|
2007
|
0.95
|
|
41
|
Crizotinib inhibits metabolic inactivation of gemcitabine in c-Met-driven pancreatic carcinoma.
|
Cancer Res
|
2013
|
0.95
|
|
42
|
Oxaliplatin activity in selected and unselected human ovarian and colorectal cancer cell lines.
|
Biochem Pharmacol
|
2008
|
0.93
|
|
43
|
Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib.
|
Mol Cancer Ther
|
2010
|
0.93
|
|
44
|
Inherited germline T790M mutation and somatic epidermal growth factor receptor mutations in non-small cell lung cancer patients.
|
J Thorac Oncol
|
2011
|
0.93
|
|
45
|
Methylenetetrahydrofolate reductase (MTHFR) C677T and thymidylate synthase promoter (TSER) polymorphisms in Indonesian children with and without leukemia.
|
Leuk Res
|
2007
|
0.93
|
|
46
|
Kinome profiling of non-canonical TRAIL signaling reveals RIP1-Src-STAT3-dependent invasion in resistant non-small cell lung cancer cells.
|
J Cell Sci
|
2012
|
0.92
|
|
47
|
Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines.
|
Mol Cancer Ther
|
2009
|
0.92
|
|
48
|
Interaction between celecoxib and docetaxel or cisplatin in human cell lines of ovarian cancer and colon cancer is independent of COX-2 expression levels.
|
Biochem Pharmacol
|
2007
|
0.91
|
|
49
|
Gene expression profiling of leukemia T-cells resistant to methotrexate and 7-hydroxymethotrexate reveals alterations that preserve intracellular levels of folate and nucleotide biosynthesis.
|
Biochem Pharmacol
|
2009
|
0.91
|
|
50
|
Molecular targets of gemcitabine action: rationale for development of novel drugs and drug combinations.
|
Curr Pharm Des
|
2012
|
0.91
|
|
51
|
Sensitivity to ionizing radiation and chemotherapeutic agents in gemcitabine-resistant human tumor cell lines.
|
Int J Radiat Oncol Biol Phys
|
2002
|
0.91
|
|
52
|
Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis.
|
Biochem Pharmacol
|
2002
|
0.90
|
|
53
|
Thymidylate synthase inhibitors for non-small cell lung cancer.
|
Expert Opin Investig Drugs
|
2011
|
0.90
|
|
54
|
Synthesis of 2-fluoro N(10)-substituted acridones and their cytotoxicity studies in sensitive and resistant cancer cell lines and their DNA intercalation studies.
|
Arch Pharm (Weinheim)
|
2009
|
0.90
|
|
55
|
Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1).
|
Biochem Pharmacol
|
2004
|
0.90
|
|
56
|
ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates.
|
Cancer Res
|
2005
|
0.89
|
|
57
|
Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.
|
Lung Cancer
|
2012
|
0.89
|
|
58
|
Activity and substrate specificity of pyrimidine phosphorylases and their role in fluoropyrimidine sensitivity in colon cancer cell lines.
|
Int J Biochem Cell Biol
|
2006
|
0.89
|
|
59
|
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer.
|
Curr Pharm Des
|
2013
|
0.88
|
|
60
|
Dynamics of antifolate transport via the reduced folate carrier and the membrane folate receptor in murine leukaemia cells in vitro and in vivo.
|
Cancer Chemother Pharmacol
|
2008
|
0.88
|
|
61
|
Gender, cytidine deaminase, and 5-aza/decitabine--letter.
|
Clin Cancer Res
|
2013
|
0.88
|
|
62
|
Positioning of aminopeptidase inhibitors in next generation cancer therapy.
|
Amino Acids
|
2014
|
0.88
|
|
63
|
Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer.
|
Neoplasia
|
2013
|
0.87
|
|
64
|
Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression after administration of 5-fluorouracil to patients with colorectal cancer.
|
Int J Cancer
|
2007
|
0.87
|
|
65
|
USP1 deubiquitinase: cellular functions, regulatory mechanisms and emerging potential as target in cancer therapy.
|
Mol Cancer
|
2013
|
0.87
|
|
66
|
Irinotecan-induced cytotoxicity to colon cancer cells in vitro is stimulated by pre-incubation with trifluorothymidine.
|
Eur J Cancer
|
2006
|
0.86
|
|
67
|
Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients.
|
Pharmacogenomics
|
2011
|
0.86
|
|
68
|
Folate deprivation induces BCRP (ABCG2) expression and mitoxantrone resistance in Caco-2 cells.
|
Int J Cancer
|
2008
|
0.86
|
|
69
|
N-Hydroxyindole-based inhibitors of lactate dehydrogenase against cancer cell proliferation.
|
Eur J Med Chem
|
2011
|
0.86
|
|
70
|
TAS-102: more than an antimetabolite.
|
Lancet Oncol
|
2012
|
0.86
|
|
71
|
Role of E3 ubiquitin ligases in lung cancer.
|
World J Clin Oncol
|
2013
|
0.86
|
|
72
|
Quantitative real time PCR of deoxycytidine kinase mRNA by Light Cycler PCR in relation to enzyme activity and gemcitabine sensitivity.
|
Cancer Lett
|
2004
|
0.85
|
|
73
|
The role of multidrug resistance proteins MRP1, MRP2 and MRP3 in cellular folate homeostasis.
|
Biochem Pharmacol
|
2003
|
0.85
|
|
74
|
EO9 (Apaziquone): from the clinic to the laboratory and back again.
|
Br J Pharmacol
|
2013
|
0.85
|
|
75
|
DNA-bound platinum is the major determinant of cisplatin sensitivity in head and neck squamous carcinoma cells.
|
PLoS One
|
2013
|
0.85
|
|
76
|
Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib.
|
Cell Oncol (Dordr)
|
2015
|
0.84
|
|
77
|
The impact of folate status on the efficacy of colorectal cancer treatment.
|
Curr Drug Metab
|
2011
|
0.84
|
|
78
|
Molecular mechanism underlying the synergistic interaction between trifluorothymidine and the epidermal growth factor receptor inhibitor erlotinib in human colorectal cancer cell lines.
|
Cancer Sci
|
2009
|
0.84
|
|
79
|
Intracellular trafficking of MDR transporters and relevance of SNPs.
|
Curr Top Med Chem
|
2009
|
0.83
|
|
80
|
Cellular folate status modulates the expression of BCRP and MRP multidrug transporters in cancer cell lines from different origins.
|
Mol Cancer Ther
|
2009
|
0.83
|
|
81
|
Antitumor activity and biodistribution of cisplatin nanocapsules in nude mice bearing human ovarian carcinoma xenografts.
|
Anticancer Drugs
|
2008
|
0.83
|
|
82
|
Synthesis and biological activity of a gemcitabine phosphoramidate prodrug.
|
J Med Chem
|
2007
|
0.83
|
|
83
|
miR-211 modulates gemcitabine activity through downregulation of ribonucleotide reductase and inhibits the invasive behavior of pancreatic cancer cells.
|
Nucleosides Nucleotides Nucleic Acids
|
2014
|
0.82
|
|
84
|
Pemetrexed induced thymidylate synthase inhibition in non-small cell lung cancer patients: a pilot study with 3'-deoxy-3'-[¹⁸F]fluorothymidine positron emission tomography.
|
PLoS One
|
2013
|
0.82
|
|
85
|
Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
|
Curr Top Med Chem
|
2012
|
0.82
|
|
86
|
Role of CYB5A in pancreatic cancer prognosis and autophagy modulation.
|
J Natl Cancer Inst
|
2013
|
0.82
|
|
87
|
Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back.
|
Int J Cancer
|
2013
|
0.82
|
|
88
|
EGF receptor-targeted therapy in non-small-cell lung cancer: role of germline polymorphisms in outcome and toxicity.
|
Future Oncol
|
2012
|
0.82
|
|
89
|
The relation between deoxycytidine kinase activity and the radiosensitising effect of gemcitabine in eight different human tumour cell lines.
|
BMC Cancer
|
2006
|
0.82
|
|
90
|
Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer.
|
Curr Pharm Des
|
2013
|
0.82
|
|
91
|
Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126.
|
Invest New Drugs
|
2011
|
0.82
|
|
92
|
Pharmacological aspects of the enzastaurin-pemetrexed combination in non-small cell lung cancer (NSCLC).
|
Curr Drug Targets
|
2010
|
0.82
|
|
93
|
In vitro sensitivity and cross-resistance to deoxynucleoside analogs in childhood acute leukemia.
|
Haematologica
|
2006
|
0.81
|
|
94
|
Determinants of trifluorothymidine sensitivity and metabolism in colon and lung cancer cells.
|
Anticancer Drugs
|
2005
|
0.81
|
|
95
|
Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy.
|
Pharmacogenomics
|
2011
|
0.81
|
|
96
|
Cellular pharmacology of multi- and duplex drugs consisting of ethynylcytidine and 5-fluoro-2'-deoxyuridine.
|
Invest New Drugs
|
2009
|
0.80
|
|
97
|
Detection of an alternatively spliced form of deoxycytidine kinase mRNA in the 2'-2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000.
|
Biochem Pharmacol
|
2004
|
0.80
|
|
98
|
MAPK p38 and JNK have opposing activities on TRAIL-induced apoptosis activation in NSCLC H460 cells that involves RIP1 and caspase-8 and is mediated by Mcl-1.
|
Apoptosis
|
2013
|
0.80
|
|
99
|
Allopurinol enhances the activity of hypoxanthine-guanine phosphoribosyltransferase in inflammatory bowel disease patients during low-dose thiopurine therapy: preliminary data of an ongoing series.
|
Nucleosides Nucleotides Nucleic Acids
|
2011
|
0.80
|
|
100
|
3'-Azido-2',3'-dideoxythymidine induced deficiency of thymidine kinases 1, 2 and deoxycytidine kinase in H9 T-lymphoid cells.
|
Biochem Pharmacol
|
2002
|
0.80
|
|
101
|
In vitro optimization of non-small cell lung cancer activity with troxacitabine, L-1,3-dioxolane-cytidine, prodrugs.
|
J Med Chem
|
2007
|
0.80
|
|
102
|
Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?
|
Pharmacogenomics
|
2012
|
0.80
|
|
103
|
Sulfasalazine down-regulates the expression of the angiogenic factors platelet-derived endothelial cell growth factor/thymidine phosphorylase and interleukin-8 in human monocytic-macrophage THP1 and U937 cells.
|
Mol Pharmacol
|
2004
|
0.80
|
|
104
|
Staurosporine increases toxicity of gemcitabine in non-small cell lung cancer cells: role of protein kinase C, deoxycytidine kinase and ribonucleotide reductase.
|
Anticancer Drugs
|
2010
|
0.79
|
|
105
|
A single nucleotide polymorphism in EZH2 predicts overall survival rate in patients with cholangiocarcinoma.
|
Oncol Lett
|
2013
|
0.79
|
|
106
|
Impact of cytidine deaminase polymorphisms on toxicity after gemcitabine: the question is still ongoing.
|
J Clin Oncol
|
2010
|
0.79
|
|
107
|
Modulation of folate uptake in cultured human colon adenocarcinoma Caco-2 cells by dietary compounds.
|
Eur J Nutr
|
2007
|
0.79
|
|
108
|
On therapeutic drug monitoring of thiopurines in inflammatory bowel disease; pharmacology, pharmacogenomics, drug intolerance and clinical relevance.
|
Curr Drug Metab
|
2009
|
0.79
|
|
109
|
Thymidylate synthase inhibitors.
|
Cancer Chemother Biol Response Modif
|
2002
|
0.79
|
|
110
|
Polymorphisms in the enhancer region of the thymidylate synthase gene are associated with thymidylate synthase levels in normal tissues but not in malignant tissues of patients with colorectal cancer.
|
Clin Colorectal Cancer
|
2009
|
0.79
|
|
111
|
Disparate mechanisms of antifolate resistance provoked by methotrexate and its metabolite 7-hydroxymethotrexate in leukemia cells: implications for efficacy of methotrexate therapy.
|
Blood
|
2004
|
0.79
|
|
112
|
Effects of antifolates on the binding of 5-fluoro-2'-deoxyuridine monophosphate to thymidylate synthase.
|
Biochem Pharmacol
|
2002
|
0.79
|
|
113
|
XIII International Charles Heidelberger Symposium and 50 Years of Fluoropyrimidines in Cancer Therapy Held on september 6 to 8, 2007 at New York University Cancer Institute, Smilow Conference Center.
|
Mol Cancer Ther
|
2009
|
0.79
|
|
114
|
DNA copy number profiles correlate with outcome in colorectal cancer patients treated with fluoropyrimidine/antifolate-based regimens.
|
Curr Drug Metab
|
2011
|
0.78
|
|
115
|
Characterization of and protection from neurotoxicity induced by oxaliplatin, bortezomib and epothilone-B.
|
Anticancer Res
|
2014
|
0.78
|
|
116
|
The effect of G-CSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia.
|
Int J Oncol
|
2004
|
0.78
|
|
117
|
Folates provoke cellular efflux and drug resistance of substrates of the multidrug resistance protein 1 (MRP1).
|
Cancer Chemother Pharmacol
|
2014
|
0.78
|
|
118
|
Radiosensitization by thymidine phosphorylase inhibitor in thymidine phosphorylase negative and overexpressing bladder cancer cell lines.
|
Nucleosides Nucleotides Nucleic Acids
|
2014
|
0.78
|
|
119
|
An expedient assay for determination of gemcitabine and its metabolite in human plasma using isocratic ion-pair reversed-phase high-performance liquid chromatography.
|
Ther Drug Monit
|
2003
|
0.78
|
|
120
|
TFAP2E-DKK4 and chemoresistance in colorectal cancer.
|
N Engl J Med
|
2012
|
0.77
|
|
121
|
High-dose 5-Fluorouracil with uridine-diphosphoglucose rescue increases thymidylate synthase inhibition but not 5-Fluorouracil incorporation into RNA in murine tumors.
|
Oncology
|
2002
|
0.77
|
|
122
|
Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin.
|
Med Oncol
|
2010
|
0.77
|
|
123
|
Thymidylate synthase inhibitors.
|
Cancer Chemother Biol Response Modif
|
2003
|
0.77
|
|
124
|
The use of capecitabine in daily practice: a study on adherence and patients' experiences.
|
Patient Prefer Adherence
|
2012
|
0.77
|
|
125
|
Design and synthesis of quinazolinone tagged acridones as cytotoxic agents and their effects on EGFR tyrosine kinase.
|
Arch Pharm (Weinheim)
|
2014
|
0.77
|
|
126
|
Enhanced levels of deoxycytidine kinase and thymidine kinase 1 and 2 after pulsed low dose rate irradiation as an adaptive response to radiation.
|
Oncol Rep
|
2001
|
0.77
|
|
127
|
Gout and hyperuricemia in Japan: perspectives for international research on purines and pyrimidines in man.
|
Nucleosides Nucleotides Nucleic Acids
|
2011
|
0.77
|
|
128
|
Low folate conditions may enhance the interaction of trifluorothymidine with antifolates in colon cancer cells.
|
Cancer Chemother Pharmacol
|
2005
|
0.77
|
|
129
|
Influence of polymorphisms on EGFR targeted therapy in non-small-cell lung cancer.
|
Front Biosci (Landmark Ed)
|
2011
|
0.77
|
|
130
|
Successful treatment of renal cell carcinoma with sorafenib after effective but hepatotoxic sunitinib exposure.
|
J Clin Oncol
|
2012
|
0.77
|
|
131
|
A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients.
|
Pharmacogenomics
|
2014
|
0.77
|
|
132
|
Antiproliferative effects of novel aliphatic acetogenin analogs against aggressive solid tumor cell lines.
|
In Vivo
|
2011
|
0.76
|
|
133
|
Physicochemical properties of novel protein kinase inhibitors in relation to their substrate specificity for drug transporters.
|
Expert Opin Drug Metab Toxicol
|
2015
|
0.76
|
|
134
|
O6-methylguanine-DNA-methyltransferase promoter demethylation is involved in basic fibroblast growth factor induced resistance against temozolomide in human melanoma cells.
|
Mol Cancer Ther
|
2007
|
0.76
|
|
135
|
Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine.
|
Expert Opin Investig Drugs
|
2012
|
0.76
|
|
136
|
The novel thymidylate synthase inhibitor trifluorothymidine (TFT) and TRAIL synergistically eradicate non-small cell lung cancer cells.
|
Cancer Chemother Pharmacol
|
2014
|
0.76
|
|
137
|
Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells.
|
Mol Cancer Ther
|
2009
|
0.76
|
|
138
|
In vivo and in vitro activity and mechanism of action of the multidrug cytarabine-L-glycerylyl-fluorodeoxyuridine.
|
Nucleosides Nucleotides Nucleic Acids
|
2007
|
0.76
|
|
139
|
Cytotoxicity of sphingoid marine compound analogs in mono- and multilayered solid tumor cell cultures.
|
Invest New Drugs
|
2006
|
0.76
|
|
140
|
"One marker does not fit all": additional translational and validation studies are needed to identify faithful predictors of pemetrexed activity in mesothelioma.
|
J Thorac Oncol
|
2013
|
0.75
|
|
141
|
Pharmacogenetics of non-small cell lung cancer (NSCLC): time to "work it out"?
|
Curr Pharm Des
|
2014
|
0.75
|
|
142
|
Integrating collection of biospecimens in clinical trials: the approach of the European organization for research and treatment of cancer.
|
Biopreserv Biobank
|
2011
|
0.75
|
|
143
|
Rapid Homogeneous Immunoassay to Quantify Gemcitabine in Plasma for Therapeutic Drug Monitoring.
|
Ther Drug Monit
|
2017
|
0.75
|
|
144
|
Aphidicolin decreases ex vivo resistance to cytosine arabinoside in childhood acute leukaemia.
|
Oncol Rep
|
2003
|
0.75
|
|
145
|
The effect of fluoropyrimidines with or without thymidine phosphorylase inhibitor on the expression of thymidine phosphorylase.
|
Eur J Pharmacol
|
2004
|
0.75
|
|
146
|
Novel developments in metabolic disorders of purine and pyrimidine metabolism and therapeutic applications of their analogs.
|
Nucleosides Nucleotides Nucleic Acids
|
2014
|
0.75
|
|
147
|
Purine and pyrimidine metabolism in the fist decade of the 21st century--highlights and perspectives.
|
Nucleosides Nucleotides Nucleic Acids
|
2010
|
0.75
|
|
148
|
Molecular mechanisms underlying the role of microRNAs in resistance to epidermal growth factor receptor-targeted agents and novel therapeutic strategies for treatment of non-small-cell lung cancer.
|
Crit Rev Oncog
|
2013
|
0.75
|